What treatment options are available for patients with FVII deficiency?¶
Answer: Several hemostatic options exist; recombinant FVIIa (rFVIIa) is the preferred agent for bleeding and prophylaxis, given at doses far lower than those used in hemophilia A/B with inhibitors.
- Antifibrinolytics (TXA): usually effective for minor bleeding, procedures, and mucosal bleeding.
- rFVIIa: preferred for bleeding and prophylaxis; low doses of 15–30 mcg/kg every 4–6 h, with a single 20 mcg/kg dose for minor surgery.
- Plasma-derived FVII (pdFVII): effective but can be hard to access; 10–30 U/kg — in our experience most useful for prophylaxis.
- FFP / solvent-detergent plasma: ~10–15 mL/kg.
- 4-factor PCC: 20–30 U/kg (e.g. Octaplex, 180–480 IU/mL).
Background: FVII deficiency is the most common rare inherited coagulation disorder, with an autosomal recessive pattern (prevalence ~1:300,000–500,000 homozygous, ~1:350 heterozygous). Homozygotes or compound heterozygotes usually have severe deficiency (<10 IU/dL); heterozygotes have levels of 20–60 IU/dL. Bleeding correlates poorly with factor level — patients with severe deficiency may be asymptomatic, while heterozygotes may bleed significantly.
Source: Rare inherited coagulation disorders: no longer orphan and neglected